预测美国生物人工主动脉瓣失效的治疗方法：一种提议的模型。
Predicting Treatment of Bioprosthetic Aortic Valve Failure in the United States: A Proposed Model.
作者信息
Généreux Philippe, Leon Martin B, Dar Roy D, Puri Rishi, Rozenman Yoseph, Szerlip Molly, Yadav Pradeep K, Thourani Vinod H, Pibarot Philippe, Dvir Danny
机构信息
Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey.
Cardiovascular Research Foundation, New York, New York.
出版信息
Struct Heart. 2024 Jul 10;9(2):100339. doi: 10.1016/j.shj.2024.100339. eCollection 2025 Feb.
•Transcatheter aortic valve replacement (TAVR) is the dominant treatment for aortic stenosis; the need to treat TAVR failure is increasing.•TAVR valve-in-valve (ViV) is predicted to reach ∼42,000 procedures by 2035.•TAVR ViV will represent ∼15% of all TAVR performed by 2035.•TAVR-in-TAVR will match TAVR-in-surgical aortic valve replacement by 2028 and dominate thereafter.•To ensure the viability of TAVR ViV, the use of leaflet modification is needed.
•经导管主动脉瓣置换术（TAVR）是主动脉瓣狭窄的主要治疗方法；治疗TAVR失败的需求正在增加。
•预计到2035年，TAVR瓣中瓣（ViV）手术将达到约42,000例。
•到2035年，TAVR ViV将占所有TAVR手术的约15%。
•到2028年，TAVR-in-TAVR将与外科主动脉瓣置换术中的TAVR相匹配，并在之后占据主导地位。
•为确保TAVR ViV的可行性，需要使用瓣叶改良技术。
Zotero 插件